Description
Tucanic 150 mg is a drug containing tucatinib, a potent tyrosine linase inhibitor (TKI) designed specifically for targeted HER2-positive breast cancer. It is used in combination with other cancer treatments for the treatment and treatment of patients with advanced or metastatic HER2-positive breast cancer, including cases that have spread to the brain. Tucanic 150 mg has been developed as an oral therapy and plays an important role in improving survival and slowing disease progression in patients already exposed to previous treatments.
The structure and mechanism of action
Active Ingredient: tucatinib (150 mg)
Tucatinib is a selective, small molecule inhibitor of HER2 tyrosininase. HER2 protein (human epidermal growth factor receptor 2) promotes the growth of cancer cells. In contrast to other treatments, tucatinib selection inhibits HER2 signaling without significantly affecting EGFR (epidermal growth factor receptor) and risk of side effects associated with EGFR inhibition, such as severe skin and stomach toxicity.
Tucatinib blocks the activity of HER2 and prevents tumor cell proliferation and induced cancer cell death. It is often administered in combination with trastuzumab (a monoclonal antibody targeted for HER2) and capecitabine (chemotherapy) to improve its therapeutic efficacy.
Adaptation
Tucanic 150 mg is used in treatment.
HER2-positive metastatic breast cancer
HER2-positive progressive breast cancer spread to other organs, including the brain
Cases where previous HER2-STAR therapies such as trastuzumab, pertuzumab, and adrostuzumabemtansine (T-DM1) have been used
Dosage and administration
The recommended dose of Tucanic 150 mg (tucatinib) was 300 mg (two 150 mg tablets) and was taken orally in combination with capecitabine and trastuzumab twice daily. It is important to follow the instructions of your healthcare service provider only to maximize the effectiveness of your treatment and to minimize side effects. Administration Guidelines:
Tukanic 150Mg should be taken with or without food.
The tablet must be swallowed completely without destroying or biting.
If the dose is overlooked and is within 8 hours of the planned time, the patient should take it as soon as possible. If more than 8 hours have passed, you should skip the dose and get the next planned dose.
Avoid grapefruit and grapefruit juice as it can affect drug metabolism. Side effects and side effects
Like other drugs, 150 mg of Tukanic 150Mg acid can cause side effects ranging from mild to difficult.
Common Side Effects:
diarrhea
Nausea and vomiting
Fatigue
abdominal pain
I reduced my appetite
Dry skin or rash
headache
Increased liver enzymes
Serious side effects:
Heavy diarrhea: It can lead to dehydration and electrolyte weight. It is recommended that patients remain hydrated and let their doctor know if diarrhea remains.
Hepatotoxicity: Liver function should be monitored regularly as increased levels of liver enzymes have been reported.
Cardiotoxicity: Although less frequent than other HER2 inhibitors, cardiac function monitoring is recommended. Handshake syndrome: Pain, redness, and swelling in the hands and feet can occur, especially in combination with capecitabine.
Interstitial Lung Disease (ILD): Rare but serious lung problems can occur, where symptoms such as cough, fever, and difficulty breathing can occur.
Precautions and warnings
Pregnancy and Breastfeeding: Tukanic 150Mg can cause fetal damage. Therefore, effective birth control should be used during treatment and at least one week after the last dose. Breastfeeding is not recommended for treatment.
Liver dysfunction: Dose adjustments may be required for patients with liver damage. Drug-to-drug interaction: Tucanic can interact with certain drugs, including CYP3A substrates and inductors. Patients should inform their doctor about other medications they are taking.
Clinical efficacy and research
Tucatinib was evaluated in the HER2CLIMB study, a central phase III clinical trial that showed significant benefits in patients with HER2-positive metastatic breast cancer. Reported in this study:
Reduced risk of disease progression or death when tucatinib is added to trastuzumab and capecitabine.
Improved overall survival (OS) and progressive survival (PFS). The efficacy of patients with brain metastasis is one of the few HER2 star therapies with proven efficacy in the treatment of central nervous system involvement.
Storage and Handling
Store 150 mg of Tukanic 150Mg acid at room temperature (15°C-30°C) in a dry place before direct sunlight.
Keep your medication outside of your child or pet range.
Conclusion
Tukanic 150Mg (tucatinib) represents significant progression in the treatment of HER2-positive breast cancer, particularly in patients with metastatic disease or brain metastasis. Selective targeting of HER2 provides more effective and tolerant therapeutic options when used in combination with trastuzumab and capecitabine. However, it is important to maximize benefits and effectively treat potential side effects, as well as cancer therapy, proper medical surveillance, adherence to prescribed doses, and regular monitoring.
How to order IEB Pharma medicine…
Ordering our IEB Pharma Medicines is easy. Currently there is no automated ordering system on our website; we offer various options for ordering IEB Pharma Medicines.
WhatsApp: You can send a message by clicking on our WhatsApp button, and a customer service representative of IEB Pharma will assist you in placing your order.
Telegram/Messenger/WeChat: If you want to place an order on our Facebook Messenger, Telegram, or WeChat, then you can easily place an order by clicking on our message option button.
Email: You can message us at [email protected] for details about your order. We answer your call as soon as we can.
